Ryan R Cook1, Randy Torralva2, Caroline King3, Paula J Lum4, Hansel Tookes5, Canyon Foot3, Pamela Vergara-Rodriguez6, Allan Rodriguez5, Laura Fanucchi7, Gregory M Lucas8, Elizabeth N Waddell9, P Todd Korthuis9. 1. Oregon Health & Science University, Addiction Medicine Program, Portland, OR, United States. Electronic address: cookry@ohsu.edu. 2. CODA Treatment Program, Portland, OR, United States; Oregon Health & Science University, Department of Psychiatry, Portland, OR, United States. 3. Oregon Health & Science University, Addiction Medicine Program, Portland, OR, United States. 4. Division of HIV, ID & Global Medicine, University of California, San Francisco, San Francisco, CA, United States. 5. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, United States. 6. Ruth M Rothstein CORE Center, Department of Psychiatry, Cook County Health, Chicago, IL, United States. 7. Division of Infectious Diseases and Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, United States. 8. Johns Hopkins School of Medicine, Baltimore, MD, United States. 9. Oregon Health & Science University, Addiction Medicine Program, Portland, OR, United States; Johns Hopkins School of Medicine, Baltimore, MD, United States; Oregon Health & Science University-Portland State University, School of Public Health, Portland, OR, United States.
Abstract
BACKGROUND: Associations between fentanyl use and initiation and retention on medications for opioid use disorder (MOUD) are poorly understood. METHODS: Data were from a multisite clinical trial comparing extended-release naltrexone (XR-NTX) with treatment as usual (TAU; buprenorphine or methadone) to achieve HIV viral suppression among people with OUD and uncontrolled HIV disease. The exposure of interest was fentanyl use, as measured by urine drug screening. Outcomes were time to MOUD initiation, defined as date of first injection of XR-NTX, buprenorphine prescription, or methadone administration; MOUD persistence, the total number of injections, prescriptions, or administrations received over 24 weeks; and MOUD retention, having an injection, prescription, or administration during weeks 20-24. RESULTS: Participants (N = 111) averaged 47 years old and 62% were male. Just over half (57%) were Black and 13% were Hispanic. Sixty-four percent of participants tested positive for fentanyl at baseline. Participants with baseline fentanyl positivity were 11 times less likely to initiate XR-NTX than those negative for fentanyl (aHR = 0.09, 95% CI 0.03-0.24, p < .001), but there was no evidence that fentanyl use impacted the likelihood of TAU initiation (aHR = 1.50, 0.67-3.36, p = .323). Baseline fentanyl use was not associated with persistence or retention on any MOUD. CONCLUSIONS: Fentanyl use was a substantial barrier to XR-NTX initiation for the treatment of OUD in persons with uncontrolled HIV infection. There was no evidence that fentanyl use impacted partial/full agonist initiation and, once initiated, retention on any MOUD.
BACKGROUND: Associations between fentanyl use and initiation and retention on medications for opioid use disorder (MOUD) are poorly understood. METHODS: Data were from a multisite clinical trial comparing extended-release naltrexone (XR-NTX) with treatment as usual (TAU; buprenorphine or methadone) to achieve HIV viral suppression among people with OUD and uncontrolled HIV disease. The exposure of interest was fentanyl use, as measured by urine drug screening. Outcomes were time to MOUD initiation, defined as date of first injection of XR-NTX, buprenorphine prescription, or methadone administration; MOUD persistence, the total number of injections, prescriptions, or administrations received over 24 weeks; and MOUD retention, having an injection, prescription, or administration during weeks 20-24. RESULTS: Participants (N = 111) averaged 47 years old and 62% were male. Just over half (57%) were Black and 13% were Hispanic. Sixty-four percent of participants tested positive for fentanyl at baseline. Participants with baseline fentanyl positivity were 11 times less likely to initiate XR-NTX than those negative for fentanyl (aHR = 0.09, 95% CI 0.03-0.24, p < .001), but there was no evidence that fentanyl use impacted the likelihood of TAU initiation (aHR = 1.50, 0.67-3.36, p = .323). Baseline fentanyl use was not associated with persistence or retention on any MOUD. CONCLUSIONS: Fentanyl use was a substantial barrier to XR-NTX initiation for the treatment of OUD in persons with uncontrolled HIV infection. There was no evidence that fentanyl use impacted partial/full agonist initiation and, once initiated, retention on any MOUD.
Authors: Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes Journal: Am J Psychiatry Date: 2017-01-10 Impact factor: 18.112
Authors: John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch Journal: Drug Alcohol Depend Date: 2006-10-11 Impact factor: 4.492
Authors: Gregory Rudolf; Jim Walsh; Abigail Plawman; Paul Gianutsos; William Alto; Lloyd Mancl; Vania Rudolf Journal: Am J Drug Alcohol Abuse Date: 2017-08-10 Impact factor: 3.829
Authors: Mohammad Sibai; Kaitlyn Mishlen; Edward V Nunes; Frances R Levin; John J Mariani; Adam Bisaga Journal: Am J Drug Alcohol Abuse Date: 2019-12-20 Impact factor: 3.829
Authors: Denis Antoine; Andrew S Huhn; Eric C Strain; Gavin Turner; Jasmyne Jardot; Alexis S Hammond; Kelly E Dunn Journal: Am J Addict Date: 2020-06-23
Authors: Chelsea L Shover; Titilola O Falasinnu; Candice L Dwyer; Nayelie Benitez Santos; Nicole J Cunningham; Rohan B Freedman; Noel A Vest; Keith Humphreys Journal: Drug Alcohol Depend Date: 2020-09-28 Impact factor: 4.492
Authors: Jongyeon Kim; Catherine R Lesko; Anthony T Fojo; Jeanne C Keruly; Richard D Moore; Geetanjali Chander; Bryan Lau Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 20.999
Authors: Sarah Bauerle Bass; Patrick J A Kelly; Sphoorti Pandit-Kerr; Jenine Pilla; Katherine Morris; Erin Larsen; Jennifer P Wisdom; Phillip R Torralva Journal: Front Public Health Date: 2022-07-22